## **CLAIMS**

- A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of gemcitabine.
- A method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a
  pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of gemeitabine.
  - 3. A method according to claim 2 for the treatment of a cancer involving a solid tumour.
- 15 4. A pharmaceutical composition which comprises ZD6474 or a pharmaceutically acceptable salt thereof, and gemeitabine, in association with a pharmaceutically acceptable excipient or carrier.
- A kit comprising ZD6474 or a pharmaceutically acceptable salt thereof, and
  gemcitabine.
  - 6. Use of ZD6474 or a pharmaceutically acceptable salt thereof and gemcitabine in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human.

25

- 7. Use of ZD6474 or a pharmaceutically acceptable salt thereof and gemeitabine in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human.
- 30 8. Use according to claim 7 wherein the anti-cancer effect comprises an anti-tumour effect.
  - 9. A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which comprises administering to

said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of gemcitabine and before, after or simultaneously with an effective amount of ionising radiation.

5 10. A method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of gemcitabine and before, after or simultaneously with an effective amount of ionising radiation.

10

- 11. A method according to claim 10 for the treatment of a cancer involving a solid turnour.
- Use of ZD6474 or a pharmaceutically acceptable salt thereof and gemcitabine in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular
  permeability reducing effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
- Use of ZD6474 or a pharmaceutically acceptable salt thereof and gemcitabine in the manufacture of a medicament for use in the production of an anti-cancer effect in a
  warm-blooded animal such as a human which is being treated with ionising radiation.
  - 14. Use according to claim 13 wherein the anti-cancer effect comprises an anti-tumour effect.